PolyPid (PYPD) 주식 개요
폴리피드는 미충족 의료 수요를 해결하기 위해 독점적인 고분자 지질 캡슐화 매트릭스(PLEX) 기술을 사용하여 표적, 국소 투여, 서방형 치료제를 개발하는 바이오 제약 회사입니다. 자세히 보기
PYPD Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
PolyPid Ltd. 경쟁사
가격 이력 및 성과
| 과거 주가 | |
|---|---|
| 현재 주가 | US$4.84 |
| 52주 최고가 | US$5.20 |
| 52주 최저가 | US$2.44 |
| 베타 | 1.41 |
| 1개월 변동 | 4.76% |
| 3개월 변동 | 12.82% |
| 1년 변동 | 89.80% |
| 3년 변동 | -56.41% |
| 5년 변동 | -98.28% |
| IPO 이후 변동 | -99.15% |
최근 뉴스 및 업데이트
새로운 내러티브 • Apr 04
Long Regulatory And Commercial Risks Around Lead Therapy Could Eventually Reward Patient Holders
Catalysts About PolyPid PolyPid is a biopharmaceutical company developing locally and systemically delivered, long acting therapies based on its proprietary drug delivery technology, with D PLEX100 for prevention of surgical site infections as its lead program. What are the underlying business or industry changes driving this perspective?
새로운 내러티브 • Mar 19
Regulatory Tailwinds And Extended Release Platform Will Shape A Stronger Long Term Outlook
Catalysts About PolyPid PolyPid is a biopharmaceutical company focused on extended release drug delivery products such as D-PLEX100 for prevention of surgical site infections and longer acting metabolic therapies using its Kynatrix technology. What are the underlying business or industry changes driving this perspective?Recent updates
새로운 내러티브 • Apr 04
Long Regulatory And Commercial Risks Around Lead Therapy Could Eventually Reward Patient Holders
Catalysts About PolyPid PolyPid is a biopharmaceutical company developing locally and systemically delivered, long acting therapies based on its proprietary drug delivery technology, with D PLEX100 for prevention of surgical site infections as its lead program. What are the underlying business or industry changes driving this perspective?새로운 내러티브 • Mar 19
Regulatory Tailwinds And Extended Release Platform Will Shape A Stronger Long Term Outlook
Catalysts About PolyPid PolyPid is a biopharmaceutical company focused on extended release drug delivery products such as D-PLEX100 for prevention of surgical site infections and longer acting metabolic therapies using its Kynatrix technology. What are the underlying business or industry changes driving this perspective?
새로운 내러티브 • Mar 05
Long Acting Drug Delivery And Metabolic Health Pipeline Will Transform Future Prospects
Catalysts About PolyPid PolyPid is a clinical stage biopharmaceutical company focused on long acting drug delivery products such as D PLEX100 for prevention of surgical site infections and a GLP 1 receptor agonist program for metabolic disease. What are the underlying business or industry changes driving this perspective?분석 기사 • Oct 28
Is PolyPid (NASDAQ:PYPD) A Risky Investment?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Seeking Alpha • Oct 20
PolyPid set to cut 20% jobs
PolyPid (NASDAQ:PYPD) announced on Thursday a cost reduction plan, including a 20% job cut across all departments as it expects the actions to extend tits cash runway into Q3 2023. The company expects to discuss regulatory pathway for D-PLEX100 for prevention of surgical site infections in abdominal surgery with U.S. and EU regulatory authorities in Q1 2023. As of February 28, the company had 78 full-time employees.Seeking Alpha • Sep 28
PolyPid's surgical site infections treatment eligible for marketing nod submission in EU
PolyPid (NASDAQ:PYPD) on Wednesday said it had got confirmation from Europe's drug regulator that its D-PLEX100 product candidate for the treatment of surgical site infections was eligible to be submitted for a marketing authorization. The company said the product candidate was eligible for the European Medicines Agency's (EMA) centralized procedure under the therapeutic innovation criteria. "The centralized procedure allows the submission of a single marketing application to the EMA that, if approved, enables the product to be marketed in all EU member states as well as in Iceland, Liechtenstein and Norway," PYPD said in a statement. The company is currently evaluating its recently concluded phase 3 trial which evaluated D-PLEX100 for the prevention of surgical site infections in abdominal surgery. PYPD said it intends to discuss the data from the late-stage trial and potential next steps with U.S. and EU regulators in Q1 2023. PolyPid (PYPD) stock +1.2% to $1.10 in morning trading.Seeking Alpha • Sep 02
PolyPid sheds 75% as lead candidate fails in Phase 3 trial for post-surgical infections
PolyPid Ltd. (NASDAQ:PYPD) dropped ~75% in value in the pre-market trading Friday after the Israeli company announced that its lead candidate D-PLEX100 did not meet the main goal in a Phase 3 trial for the prevention of surgical site infections ((SSIs)) in abdominal surgery. The SHIELD I was designed to evaluate the joint administration of D-PLEX100 standard of care (SoC) against SoC alone arm in 970 patients out of whom 488 were part of the D-PLEX100 treatment arm and 489 were in the control arm. The trial did not achieve the primary endpoint of reduction in surgical site infections and mortality, the company said noting that in the Intent to Treat (ITT) population, D-PLEX100 and SoC (n=485) led to 23% decrease in SSIs and mortality compared to SoC alone (n=489) (p=0.1520).Seeking Alpha • Aug 10
PolyPid GAAP EPS of -$1.23 misses by $0.60
PolyPid press release (NASDAQ:PYPD): Q2 GAAP EPS of -$1.23 misses by $0.60. As of June 30, 2022, the Company had cash and cash equivalents and deposits in the amount of $23.8 million, not including the second tranche of $2.5 million from the Kreos Capital VI (Expert Fund) LP (“Kreos”) loan, which was drawn in July 2022.Seeking Alpha • Aug 03
PolyPid to get $2.6M upfront under license deal with Advanz for D-PLEX in Europe
PolyPid (NASDAQ:PYPD) signed an exclusive licensing agreement for its lead drug candidate D-PLEX100 in Europe with U.K.-based Advanz Pharma (OTCPK:CXRXF). D-PLEX100 is used for preventing surgical site infections (SSIs) in abdominal and cardiac surgeries, in Europe. Under the agreement, PolyPid will receive $2.6M upfront and development-related milestones of up to $20.9M. Upon commercialization, PolyPid will receive up to $89M in sales-related milestones, the company said in an Aug. 3 press release. In addition, PolyPid will also supply D-PLEX100 to Advanz for a transfer price and will be entitled to royalties on net sales in double-digit percentages of up to mid-twenties. "Advanz Pharma's expertise in marketing hospital-based therapies, combined with its significant resources and relationships in the region, will prove invaluable in expanding access to D-PLEX100 and delivering this much-needed therapy, if approved, to patients," said PolyPid's CEO Dikla Czaczkes Akselbrad.Seeking Alpha • Apr 19
PolyPid: Strong Pipeline, Close Catalysts
PolyPid develops a platform technology to provide locally controlled and continuous delivery of medications. Lead product candidate D-PLEX100 is investigated for the prevention of sternal and abdominal surgical site infections serving a huge market. Meaningful interim results and topline data from pivotal Phase 3 SHIELD I clinical trial will soon be published. Measured in terms of the clinical benefit of D‑PLEX100 and its estimated market size, PolyPid is clearly undervalued at present in our view.분석 기사 • Mar 18
Will PolyPid (NASDAQ:PYPD) Spend Its Cash Wisely?
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...분석 기사 • Nov 08
Here's Why We're Watching PolyPid's (NASDAQ:PYPD) Cash Burn Situation
We can readily understand why investors are attracted to unprofitable companies. For example, although...분석 기사 • Jul 15
We Think PolyPid (NASDAQ:PYPD) Can Afford To Drive Business Growth
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...분석 기사 • Mar 09
Here's Why We're Not Too Worried About PolyPid's (NASDAQ:PYPD) Cash Burn Situation
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...주주 수익률
| PYPD | US Pharmaceuticals | US 시장 | |
|---|---|---|---|
| 7D | 1.7% | 2.6% | 2.5% |
| 1Y | 89.8% | 41.5% | 26.4% |
수익률 대 산업: PYPD은 지난 1년 동안 41.5%의 수익을 기록한 US Pharmaceuticals 산업보다 더 좋은 성과를 냈습니다.
수익률 대 시장: PYPD은 지난 1년 동안 26.4%를 기록한 US 시장보다 더 좋은 성과를 냈습니다.
주가 변동성
| PYPD volatility | |
|---|---|
| PYPD Average Weekly Movement | 6.3% |
| Pharmaceuticals Industry Average Movement | 9.9% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.5% |
| 10% least volatile stocks in US Market | 3.1% |
안정적인 주가: PYPD는 지난 3개월 동안 US 시장에 비해 주가 변동성이 크지 않았습니다.
시간에 따른 변동성: PYPD의 주간 변동성(6%)은 지난 1년 동안 안정적이었습니다.
회사 소개
| 설립 | 직원 수 | CEO | 웹사이트 |
|---|---|---|---|
| 2008 | 72 | Dikla Czaczkes Akselbrad | www.polypid.com |
폴리피드는 미충족 의료 수요를 해결하기 위해 독자적인 고분자 지질 캡슐화 매트릭스(PLEX) 기술을 사용하여 표적 국소 투여 및 장기 방출 치료제를 개발하는 바이오 제약 회사입니다. 주요 제품 후보로는 큰 절개를 통해 복부 대장 수술을 받는 환자의 수술 부위 감염(SSI) 예방을 위한 중추적인 3상 확인 임상시험을 진행 중인 D-PLEX100이 있습니다. 또한 종양 내 암 치료를 위해 전임상 단계에 있는 OncoPLEX를 개발 중입니다.
PolyPid Ltd. 기초 지표 요약
| PYPD 기초 통계 | |
|---|---|
| 시가총액 | US$95.80m |
| 순이익 (TTM) | -US$33.63m |
| 매출 (TTM) | n/a |
0.0x
주가매출비율(P/S)-2.7x
주가수익비율(P/E)PYPD는 고평가되어 있습니까?
공정 가치 및 평가 분석 보기순이익 및 매출
| PYPD 손익계산서 (TTM) | |
|---|---|
| 매출 | US$0 |
| 매출원가 | US$0 |
| 총이익 | US$0 |
| 기타 비용 | US$33.63m |
| 순이익 | -US$33.63m |
최근 보고된 실적
Mar 31, 2026
다음 실적 발표일
해당 없음
| 주당순이익(EPS) | -1.76 |
| 총이익률 | 0.00% |
| 순이익률 | 0.00% |
| 부채/자본 비율 | 9.1% |
PYPD의 장기 실적은 어땠습니까?
과거 실적 및 비교 보기기업 분석 및 재무 데이터 상태
| 데이터 | 최종 업데이트 (UTC 시간) |
|---|---|
| 기업 분석 | 2026/05/26 20:09 |
| 종가 | 2026/05/26 00:00 |
| 수익 | 2026/03/31 |
| 연간 수익 | 2025/12/31 |
데이터 소스
당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.
| 패키지 | 데이터 | 기간 | 미국 소스 예시 * |
|---|---|---|---|
| 기업 재무제표 | 10년 |
| |
| 분석가 컨센서스 추정치 | +3년 |
|
|
| 시장 가격 | 30년 |
| |
| 지분 구조 | 10년 |
| |
| 경영진 | 10년 |
| |
| 주요 개발 | 10년 |
|
* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.
별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.
분석 모델 및 스노우플레이크
이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.
Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.
산업 및 섹터 지표
산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.
분석가 소스
PolyPid Ltd.는 8명의 분석가가 다루고 있습니다. 이 중 4명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
| 분석가 | 기관 |
|---|---|
| Balaji Prasad | Barclays |
| Balaji Prasad | Barclays |
| Gary Nachman | BMO Capital Markets Equity Research |